Literature DB >> 11147505

The evolution and origin of motor complications in Parkinson's disease.

J A Obeso1, M C Rodriguez-Oroz, P Chana, G Lera, M Rodriguez, C W Olanow.   

Abstract

Levodopa is the major symptomatic therapy for Parkinson's disease (PD), having revolutionized the treatment of PD and provided benefit to virtually all patients. However, after 5-10 years of treatment, levodopa therapy is complicated by the development of motor complications, which include dyskinesia and motor fluctuations. The initial long duration response to a dose of levodopa becomes progressively shorter, and periods in which the patient responds to the drug become complicated by involuntary dyskinetic movements. Thus, patients may cycle between "on" periods that are complicated by dyskinesia and "off" periods in which they are severely parkinsonian. As a consequence they may experience profound disability despite the fact that levodopa remains an effective anti-parkinson agent throughout the course of the disease. In this article we review the various motor complications associated with the treatment of PD and present current concepts on the origin of these problems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147505

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.

Authors:  R Pedrosa; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 3.  Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation.

Authors:  Nishit B Modi
Journal:  AAPS J       Date:  2017-01-24       Impact factor: 4.009

4.  Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.

Authors:  Xiao-Min Zhang; Ming Yin; Min-Hua Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-07       Impact factor: 6.150

5.  Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.

Authors:  Maowen Ba; Min Kong; Hongqi Yang; Guozhao Ma; Guoqiang Lu; Shengdi Chen; Zhenguo Liu
Journal:  Neurochem Res       Date:  2006-10-20       Impact factor: 3.996

6.  Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Authors:  Paolo Solla; Antonino Cannas; Francesco Marrosu; Maria Giovanna Marrosu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

7.  Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum.

Authors:  Min Kong; Maowen Ba; Lu Song; Zhenguo Liu
Journal:  Neurochem Res       Date:  2009-03-13       Impact factor: 3.996

8.  A new quantitative rating scale for dyskinesia in nonhuman primates.

Authors:  Lisa F Potts; Subramaniam Uthayathas; Alexander C M Greven; Bhagyalaxmi Dyavarshetty; Mary M Mouradian; Stella M Papa
Journal:  Behav Pharmacol       Date:  2015-02       Impact factor: 2.293

9.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

Review 10.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.